Similar articles

• [Glycoprotein IIb/IIIa antagonists as antithrombotic agents].

  Reikvam A, Madsen S. Reikvam A, et al. Tidsskr Nor Laegeforen. 2002 Apr 30;122(11):1118-20. Tidsskr Nor Laegeforen. 2002. PMID: 12043057 Norwegian. No abstract available.
• Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.

  Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F; European Society of Cardiology Working Group on Thrombosis. Lip GY, et al. Thromb Haemost. 2010 Jan;103(1):13-28. doi: 10.1160/TH09-08-0580. Epub 2009 Sep 30. Thromb Haemost. 2010. PMID: 20062939 Review.
• Glycoprotein inhibitors in patients on chronic anticoagulation: safe enough or too much risk?

  Marín F, Bonacasa B, Valdés M. Marín F, et al. Thromb Haemost. 2010 Jan;103(1):11-2. doi: 10.1160/TH09-10-0694. Epub 2009 Dec 1. Thromb Haemost. 2010. PMID: 20062940 No abstract available.
• [The antithrombotic-treated patient].

  Nielsen JD, Rasmussen HM, Husted SE. Nielsen JD, et al. Ugeskr Laeger. 2006 Dec 4;168(49):4296-9. Ugeskr Laeger. 2006. PMID: 17164056 Danish.
• [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].

  Nowak-Göttl U, Langer F, Limperger V, Mesters R, Trappe RU. Nowak-Göttl U, et al. Dtsch Med Wochenschr. 2014 Jun;139(24):1301-6. doi: 10.1055/s-0034-1370110. Epub 2014 Jun 3. Dtsch Med Wochenschr. 2014. PMID: 24892468 Review. German.